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Diagnostic performance of regional
cerebral blood flow images derived from
dynamic PIB scans in Alzheimer’s disease
Débora E. Peretti1 , David Vállez García1*, Fransje E. Reesink2, Janine Doorduin1, Bauke M. de Jong2,
Peter P. De Deyn2,3, Rudi A. J. O. Dierckx1 and Ronald Boellaard1
Abstract
Background: In clinical practice, visual assessment of glucose metabolism images is often used for the diagnosis of
Alzheimer’s disease (AD) through 2-[18F]-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) scans.
However, visual assessment of the characteristic AD hypometabolic pattern relies on the expertise of the reader.
Therefore, user-independent pipelines are preferred to evaluate the images and to classify the subjects. Moreover,
glucose consumption is highly correlated with cerebral perfusion. Regional cerebral blood flow (rCBF) images can
be derived from dynamic 11C-labelled Pittsburgh Compound B PET scans, which are also used for the assessment of
the deposition of amyloid-β plaques on the brain, a fundamental characteristic of AD. The aim of this study was
to explore whether these rCBF PIB images could be used for diagnostic purposes through the PMOD Alzheimer’s
Discrimination Tool.
Results: Both tracer relative cerebral flow (R1) and early PIB (ePIB) (20–130 s) uptake presented a good correlation
when compared to FDG standardized uptake value ratio (SUVR), while ePIB (1–8 min) showed a worse correlation.
All receiver operating characteristic curves exhibited a similar shape, with high area under the curve values, and
no statistically significant differences were found between curves. However, R1 and ePIB (1–8 min) had the highest
sensitivity, while FDG SUVR had the highest specificity.
Conclusion: rCBF images were suggested to be a good surrogate for FDG scans for diagnostic purposes
considering an adjusted threshold value.
Keywords: Alzheimer’s disease, PIB, Relative cerebral blood flow, PALZ
Background
Positron emission tomography (PET) imaging improves
the diagnosis of Alzheimer’s disease (AD) due to the
broad range of functional processes it assesses [1]. One
of the most common radiotracers for PET scans, both in
the clinic and in research, is 2-[18F]-fluoro-2-deoxy-D-
glucose (FDG). This radiotracer evaluates the metabol-
ism in the brain by measuring glucose consumption,
allowing for the recognition of specific disease patterns.
AD is characterized by a hypometabolic pattern that in-
cludes regions such as the precuneus, posterior cingulate
cortex, posterior temporoparietal cortex, and medial
temporal lobe [2]. The identification of the hypometa-
bolic pattern caused by the disease is of great import-
ance for clinicians during the diagnostic process.
Another advantage of using FDG-PET is that it is sensi-
tive to changes in the early stages of the disease, even in
patients without clinical symptoms of dementia [3–5].
However, visual reading of the FDG-PET images relies
on the experience of the reader [2, 6]. Therefore, differ-
ent methods of user-independent analyses have been de-
veloped to assist in the interpretation of the scans [7–9].
Previous studies have shown a link between glucose
consumption and regional cerebral blood flow (rCBF):
blood delivery across the brain increases with metabolic
demand [10, 11]. This link might allow the use of rCBF
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
* Correspondence: d.vallez-garcia@umcg.nl
1Department of Nuclear Medicine and Molecular Imaging, University Medical
Center Groningen, University of Groningen, Hanzeplein 1, 9713, GZ,
Groningen, The Netherlands
Full list of author information is available at the end of the article
Peretti et al. EJNMMI Research            (2019) 9:59 
https://doi.org/10.1186/s13550-019-0528-3
images for the classification of AD patients since regions
that have the glucose consumption affected might also
be hypoperfused. These rCBF images can be derived
from standardized uptake value ratio (SUVR) of radio-
tracers that measure the flow in the brain, such as 15O-
Water [12], the weighted average of the initial frames of
a dynamic scan [13–15], or through pharmacokinetic
modelling [16–18].
A radiotracer that is commonly used in AD trials and in
the clinic is 11C-labeled Pittsburgh Compound B (PIB).
PET scans with PIB allow the clinician to assess the depos-
ition of amyloid-β (Aβ) plaques in the brain. Therefore,
FDG and PIB images provide complementary information
that improve the diagnosis of AD [1, 19]. Yet, dual-tracer
studies can be expensive and increase patient discomfort
and exposure to radiation [17, 20]. Hence, the use of a sin-
gle tracer to assess both Aβ deposits and the hypometabo-
lism pattern in the brain at the same time would be ideal.
In this respect, using both the tracer’s binding potential
and parametric images of relative tracer flow (R1) might
provide such complementary image information concern-
ing Aβ deposition and rCBF, respectively.
Since PIB possesses high lipophilicity [21], it meets the
prerequisite to provide rCBF images that might be a
good surrogate for FDG. This hypothesis has already
been explored in previous studies, which compared FDG
scans to PIB images generated through pharmacokinetic
modelling [16–18, 22], and a time-weighted average of
the first frames of a dynamic PIB scan [13, 22–25].
A commonly known tool for the automated discrimin-
ation of AD patients is PMOD Alzheimer’s Discrimination
Tool (PALZ). The user provides PALZ with the FDG im-
ages of a subject, which is compared to a database of
healthy controls. PALZ estimates how different is the me-
tabolism pattern of the provided image from a group of
typical healthy subjects [6], and gives a score that helps to
determine whether the subject presents an abnormal scan.
Although this automated discrimination tool was designed
for FDG, rCBF images might provide similar results due
to the high correlation between images.
The aim of this study was to explore whether rCBF
images, derived from dynamic PIB scans, could be used
for the diagnosis of AD using the PALZ tool from
PMOD. To this end, R1 and summed early frame images
were generated and used as input images in PALZ. The
results were then compared to the results from the FDG
scans. Correlations between scores and new thresholds
for classifying AD patients were drawn for each method.
Material and methods
Subjects
A cohort of fifty-two subjects was drawn from a larger
ongoing study at the memory clinic of the University
Medical Center Groningen (UMCG), Groningen, The
Netherlands. All subjects gave their written informed
consent to participate in the study, which was approved
by the Medical Ethical Committee of the UMCG (2014/
320). The study was conducted in agreement with the
Declaration of Helsinki and subsequent revisions.
The subjects were first diagnosed by consensus of a
multidisciplinary team based on clinical assessment fol-
lowing the guidelines of the National Institute on Aging
Alzheimer’s Association criteria (NIA-AA) [26] for the
AD patients, and on the Petersen criteria [27] for the
MCI patients. Healthy subjects presented no cognitive
complaints and a mini-mental state exam score higher
than 28. Then, all subjects underwent two PET scans
and a T1-3D magnetic resonance imaging (MRI). After
this, clinical diagnoses were reconsidered under the Na-
tional Institute on Aging and the Alzheimer’s Associ-
ation Research Framework [28]. Subjects were then
reclassified as AD, MCI+ (mild cognitive impairment
with Aβ deposition), MCI− (mild cognitive impairment
or other dementia without Aβ deposition), or healthy
controls (HC). Positivity or negativity regarding Aβ de-
position was done by consensus of visual inspection by
experts. A summary of the demographic characteristics
is shown in Table 1.
PET acquisition
All subjects underwent a static FDG-PET and a dynamic
PIB-PET examination. Scans were performed with either
a Siemens Biograph 40mCT or 64mCT scanner (Sie-
mens Medical Solution, USA). Since both systems are of
the same vendor and of the same generation, the acqui-
sition and reconstruction protocols were harmonized,
and the calibration of the systems was equally done; no
difference between data provided by the different scan-
ners was expected. Nonetheless, a t test comparing the
results provided by the different scanners showed that
there were no statistically significant differences between
them. Patients were in standard resting conditions with
eyes closed during the scans. The radiotracers were syn-
thesized at the radiopharmacy facility at the Nuclear
Medicine and Molecular Imaging department at the
UMCG, according to Good Manufacturing Practice, and
were administered via venous cannula. The subjects had
both scans performed on the same month, with the FDG
taking place at least 90 min after PIB injection, with the
Table 1 Demographic characteristics of subjects
AD (n = 15) MCI+ (n = 11) MCI− (n = 10) HC (n = 16)
Sex
Male 9 7 8 11
Female 6 4 2 5
Age (years) 65 ± 8 65 ± 5 67 ± 9 69 ± 5
MMSE score 25 ± 3 27 ± 2 24 ± 7 30 ± 1
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exception of five subjects, who had a delay of up to 4
months between scans.
The dynamic PIB-PET acquisitions started 10 s before
tracer injection (375 ± 50MBq) and lasted at least 60
min (frames: 7 × 10 s, 3 × 30 s, 2 × 60 s, 2 × 120 s, 2 × 180
s, 5 × 300 s, and 2 × 600 s). The static FDG-PET scans
were acquired 30min after injection (203 ± 8) and lasted
for 20 min. All subjects were fasted for at least 6 h be-
fore injection, and glucose levels in plasma were mea-
sured before the scan, and the PET scan was only
performed if glucose levels were lower than 7mmol/l
[29]. All PET images were reconstructed from list-mode
data using 3D OSEM (3 iterations and 24 subsets), point
spread function correction, and time-of-flight. The
resulting images had a matrix of 400 × 400 × 111, with
isotropic 2 mm voxels, and smoothed 2-mm Gaussian
filter at full width and half maximum (FWHM).
Image processing
The PMOD software package (version 3.8; PMOD Tech-
nologies LLC) was used for image registration and data
analysis. The MRI scans were normalized to the Mon-
treal Neurological Institute (MNI) space using tissue
probability maps [30]. The PIB-PET images were first
corrected for motion (in case of any) using the averaged
first 13 frames as reference and then aligned to the indi-
vidual MRI. The Hammers atlas [31] was used to draw
the volume of interest (VOI) of the grey matter from the
cerebellum. All PET images were smoothed using a 6-
mm Gaussian filter at FWHM, and all voxels outside of
the brain were masked.
The R1 parametric images were generated by pharma-
cokinetic modelling on a voxel level of the PIB-PET
scans in individual space. The simplified reference tissue
model 2 (SRTM2) [32] was chosen for this analysis [33],
with the grey matter from the cerebellum as the refer-
ence tissue [34–37]. A first estimate of the binding po-
tential (BPND) was done using the simplified reference
tissue (SRTM) [38], so the efflux parameter of the refer-
ence region (k2′) could be fixed. This parameter was
taken as the median value from all voxels with a BPND
higher than 0.05. Then, SRTM2 was applied with a re-
striction on the range of the apparent efflux rate con-
stant values, with a minimum of 0.01 and a maximum of
0.03, and 80 basis functions to generate the final R1
parametric maps.
The early-stage PIB (ePIB) distribution images were
generated using the time-weighted average of the frames
corresponding to the intervals of 20 to 130 s and 1 to 8
min. These intervals were chosen because previous stud-
ies have found that 20 to 130 s was the best interval to
discriminate between patients and healthy subjects [22],
and 1 to 8 min have shown the best correlation with
FDG scans [24]. Then, the standardized uptake value
ratios (SUVR) were calculated by dividing each voxel of
the image by the ratio of the injected dose and body
weight of the subject and normalizing to the average
value of the reference region (i.e. grey matter of the
cerebellum).
To compare with the FDG-PET images, the FDG
SUVR images were generated in the same manner as the
ePIB SUVR, also using the grey matter of the cerebellum
as the reference region.
For each subject, an FDG SUVR, R1, ePIB (20–130 s),
and ePIB (1–8 min) were generated and evaluated by
PALZ (v3.9, PMOD Technologies LLC), which gave a
PETSCORE per image for each method according to how
much the regions typically affected by AD deviated from
what is expected of a healthy person. An overview of the
steps taken for analysing the images is provided in
Additional file 1.
Statistical analysis
An ANOVA per method was performed to check if the
groups presented significantly different PETSCORES for
each method. Then, a pairwise t test was done to com-
pare the significance between groups within methods.
For this test, the p values were adjusted for multiple
comparisons using the Holm method [39].
A general linear model was used to explore the rela-
tionship between the PETSCORES of each PIB-derived
image (independent variable) and the FDG SUVR
(dependent variable) for all subjects. A p value of 0.05
was used as a significance threshold for all analyses. No
correction for multiple comparisons was made.
A Bland-Altman plot was made to evaluate the agree-
ment between the PETSCORE measured by PIB-derived
methods and FDG SUVR. The difference between scores
was plotted against the FDG SUVR PETSCORES, since
these scores were considered the reference values [40].
Furthermore, linear regressions were made to assess the
bias of each rCBF measure compared to the FDG SUVR
PETSCORES.
Receiver-operating characteristic (ROC) curves were
plotted to estimate the sensitivity and specificity of
each method using Youden’s method [41], using only
the PETSCORE from the AD and HC groups, since
PALZ was developed to differentiate AD from healthy
subjects, and not between different types of dementia.
DeLong’s test was applied to find if there was a cor-
relation between the rCBF and FDG SUVR curves
[42]. All results were analysed using RStudio (version
1.1.456, R version 3.5.1 [43]).
Results
PETSCORES
In general terms, the FDG SUVR images were in agree-
ment with the pattern expected from the literature
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(Fig. 1), showing a hypometabolic pattern for the AD
group, while the HC subjects presented no abnormal
cortical uptake of the tracers. The resemblance between
the R1 and ePIB when compared to the FDG SUVR was
also notable, with similar AD patterns of decreased flow
on the parietal lobe, for example.
The distribution of the PETSCORES for each method
for all subjects is shown in Fig. 2. In general, all methods
presented a statistically significant difference between
groups (p < 0.05). All methods were also able to differen-
tiate between the AD and HC groups, but none of them
was capable of distinguishing between MCI+ and MCI−.
While the FDG SUVR was able to show a statistically
significant difference between the HC and both MCI+
and MCI− groups, of the rCBF methods, only R1 pre-
sented a significant difference between the HC and
MCI+ groups. Means, standard deviations, and range of
the scores of all groups for all methods can be seen in
Additional file 2: Table S2.
Correlation of scores from FDG SUVR, R1, and ePIB
The scatter plots of the scores given to the FDG SUVR
images suggest a high correlation with the images pro-
vided by the rCBF images (Fig. 3). R1 presented a
correlation of 0.90 with the FDG SUVR, which was the
highest correlation across all rCBF methods. The scores
from FDG SUVR were highly predictive of the ones from
R1, accounting for 81% of variability (R
2 = 0.81, p < 0.001,
intercept = 0.90, slope = 0.74). The scores from ePIB
(20–130 s) also presented a high correlation as compared
to the ones from FDG SUVR (0.87), but the predictabil-
ity of the method was lower, 74% (R2 = 0.74, p < 0.001,
intercept = 1.20, slope = 0.71). While ePIB (1–8 min)
PETSCORES also presented a high correlation as com-
pared to the ones from FDG SUVR, of 0.82, this method
was not as predictive as the other two, accounting for
66% of the variability only (R2 = 0.66, p < 0.001, inter-
cept = 0.83, slope = 0.55).
Bias assessment
The bias found between FDG SUVR and rCBF PET-
SCORES was monophasic for the R1 and ePIB (20–130 s)
methods, meaning that, in general, they overestimated
the PETSCORES, of 26% for the R1 (slope = -0.26, inter-
cept = 0.9), and 29% for the ePIB (20–130 s) (slope =
-0.29, intercept = 1.20). Meanwhile, the ePIB (1-8 min)
method presented a biphasic relationship (slope = -0.45,
intercept = 0.83): it overestimates the PETSCORES of the
Fig. 1 Representative studies. Transaxial slices of the brain are shown. From left to right: FDG SUVR images, R1 parametric maps, ePIB (20–130 s),
and ePIB (1–8 min) images. On the first row, images from an AD patient; on the second, an MCI+ subject; on the third, an MCI− subject; and at
the bottom, an HC subject. All colour scales are adjusted to the same range
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HC group by approximately 50% while underestimating
the AD group by nearly 19%. In summary, the R1
method presented the smallest bias of all methods and
this bias was larger for the HC subjects than for the AD
patients (Fig. 4) [44, 45].
ROC curves
With the ROC curves (Fig. 4), it was possible to find a
new PETSCORE threshold for classifying the subjects as
AD or HC for each of the rCBF methods. The optimal
threshold for the best differentiation of the groups was
of 2.22 for the R1 method, with a sensitivity of 0.87 and
a specificity of 1. The second highest threshold was 2.08,
from the ePIB (20–130 s) method, with a sensitivity of
0.93 and a specificity of 0.94. The ePIB (1–8 min)
method resulted in a threshold of 1.50 for differentiating
the groups, with a sensitivity of 0.93 and a specificity of
0.81. The ROC curves also showed that the area under
the curve was high for all methods, the highest being for
the FDG SUVR (0.99), followed by ePIB (20–130 s)
(0.94), R1 (0.92), and ePIB (1–8 min) (0.89). No statisti-
cally significant differences were found between the
rCBF and FDG SUVR curves.
Discussion
The aim of this study was to use rCBF images derived
from PIB-PET scans as a surrogate for FDG through an
automated discrimination tool. The tool used in this
work was PALZ, from PMOD Technologies. PALZ gives
the images a PETSCORE and classifies the subjects as AD
or not based on a threshold of 1. This tool uses FDG-
PET scans for the diagnosis of the subjects, but since
metabolism and blood flow in the brain are highly corre-
lated [10], this tool might also be used to distinguish be-
tween groups using rCBF images. Furthermore, the most
recent guidelines for AD studies require Aβ imaging for
the diagnosis of AD [46]. Therefore, the use of PIB-
derived rCBF images in place of FDG scans, since PIB is
already used for Aβ imaging, might be of advantage
since it reduces costs and patient discomfort and expos-
ure to radiation.
The distribution of the PETSCORES showed a clear dis-
tinction between methods, with the FDG SUVR PET-
SCORES being smaller than the ones from rCBF images,
especially for the HC group (Fig. 2). It can also be seen
that FDG SUVR, R1, and ePIB (20–130 s) PETSCORES
presented a clearer distinction between groups than ePIB
(1–8 min). This suggests that ePIB (1–8 min) might not
be an optimal method to diagnose patients, as it has
already been observed in a previous study [22]. No
significant distinction was found between MCI+ and
MCI− groups, which was expected since PALZ was not
developed to differentiate between diseases, but only to
distinguish the AD patients from the HC subjects.
Overall, the high correlation between PETSCORES pro-
vided by different methods indicates that rCBF images
Fig. 2 Distribution of PETSCORES per method. Distribution of subjects’ PETSCORES from FDG SUVR, R1, ePIB (20–130 s), and ePIB (1–8min) respectively
from left to right. Darkest grey boxes represent data from the AD group; dark grey represents MCI+ subjects; light grey represents MCI−; and white
represents HC. A dashed line at PETSCORE = 1 represents the threshold from PALZ for the classification of AD patients. The stars represent
the differences between the groups that are statistically significant
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might be a good surrogate to FDG SUVR images. How-
ever, the slopes and intercepts of the linear regressions
suggest that the threshold should be adjusted depending
on the method used to generate the images. Further-
more, the bias between scores was different depending
on the group, with a smaller bias for the AD patients
than for the HC subjects. This difference might be re-
lated to the fact that rCBF images have a better correl-
ation with FDG SUVR in patients with more binding of
PIB than in subjects with no specific binding in cortical
matter, which is the case for the HC subjects [22].
Moreover, in a comparison of each of the rCBF methods
individually with FDG SUVR, R1 seemed to outperform
both ePIB methods. The higher correlation and small bias
from this method lead to the conclusion that the R1 images
might be the method of preference to substitute FDG-PET
scans when an automated tool to differentiate subjects is
used, as was suggested by previous studies [22, 23].
Fig. 3 Scatter and Bland-Altman plots. Scatter plots (first column) showing PETSCORES from R1 parametric maps (top), ePIB (20–130 s) (middle), and
ePIB (1–8 min) images (bottom) (y-axis), and from FDG SUVR (x-axis). The dashed lines display the identity line. Results of the linear regression are
given in boxes at the bottom right corner. Bland-Altman plots (second column) showing the difference between the PETSCORES provided by R1
(top), ePIB (20–130 s) (middle), and ePIB (1–8 min) and FDG SUVR. The full line is at the mean difference value for all scores, and the dashed lines
delimit the 95% agreement interval (at mean ± 1.96 × standard deviation). Data are arranged according to subject group: circles represent the AD,
triangles the MCI+, squares the MCI−, and cross the HC group
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Additionally, due to their high sensitivity and the fact
that its ROC curve was not significantly different from
those seen with FDG SUVR, rCBF images with an ad-
justed threshold are able to make a satisfactory distinction
between groups for diagnostic purposes. The different
thresholds found for each rCBF method suggest that, al-
though they measure the same parameter, they do not
yield the same results. This might be due to the fact that
ePIB methods might be affected by some tracer binding
already early after tracer administration, while R1 is a
measure of only flow relative to that of the cerebellum.
Furthermore, it is important to mention that the same
data was used to estimate the new threshold for classifica-
tion of subjects and to estimate its performance, which
might have led to overfitting. Therefore, the area under
the ROC curve may provide a better performance estimate
than the sensitivity and specificity results.
Although the results presented in the previous section
show a good correlation between rCBF and FDG SUVR,
these results should be taken with caution. PALZ pipeline
(Additional file 2: Table S1) includes comparing the input
image with a database of FDG scans of healthy volunteers,
which might have declined the precision of the resulting
rCBF scores. Therefore, even though the PALZ works for
rCBF images given an adjusted threshold, the classification
of the images could be improved by providing a tracer-
specific database of HC subjects. Furthermore, the intro-
duction of the MCI+ and MCI− groups might have
affected the results. This is due to the fact that PALZ is
designed and validated only for the differentiation of AD
patients from HC, as mentioned above. But previous stud-
ies have shown that PALZ is more sensitive to disease pro-
gression than are clinical tests in the MCI group [2, 47].
For this reason, the MCI group was also included in this
analysis. Moreover, there is still a need of longitudinal
studies to assess changes in R1 with the disease progres-
sion, since R1 has shown not to be as sensitive as FDG in
scenarios where small effect sizes are relevant. Further-
more, a limited number of subjects for setting the new
threshold were used in this study; an increased number of
patients could improve the accuracy of the threshold. In
addition, the diagnosis of the patients was done based on
the visual assessment of the images, which might have in-
troduced some bias in the performance of PALZ, overesti-
mating the performance of the tool.
Conclusion
The present study had the goal of using PIB-derived rCBF
images as a surrogate for FDG-PET scans to classify sub-
jects as AD patients or healthy individuals using the tool
PALZ. The various methods of generating the rCBF
method resulted in different PETSCORES for the images
and, therefore, distinct correlations with FDG scores and
thresholds for classifying the subjects. The results pre-
sented here suggest that R1 parametric maps might be the
Fig. 4 ROC plots. ROC plot with the curves of FDG SUVR (solid line), R1 (dashed line), ePIB (20–130 s) (dotted line), and ePIB (1–8min) (dot dashed line)
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best approach to generate rCBF images for diagnostic pur-
poses provided that the threshold for classification is ad-
justed. Further research should focus on exploring how
PETSCORES correlate with disease progression in longitu-
dinal studies.
Additional files
Additional file 1: An overview of the steps taken for analysing images.
(DOCX 20 kb)
Additional file 2: Table S1. Mean ± SD and range [minimum–
maximum] of all methods per group. (DOCX 14 kb)
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